DE10349979B4 - Medikamentöse gezielte lokale Lipolyse - Google Patents

Medikamentöse gezielte lokale Lipolyse Download PDF

Info

Publication number
DE10349979B4
DE10349979B4 DE10349979A DE10349979A DE10349979B4 DE 10349979 B4 DE10349979 B4 DE 10349979B4 DE 10349979 A DE10349979 A DE 10349979A DE 10349979 A DE10349979 A DE 10349979A DE 10349979 B4 DE10349979 B4 DE 10349979B4
Authority
DE
Germany
Prior art keywords
phospholipid
acid
use according
weight
phosphatidylcholine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE10349979A
Other languages
German (de)
English (en)
Other versions
DE10349979A1 (de
Inventor
Peter Dr. Boderke
Rainer Dr. Pooth
Juergen Dr. Sandow
Matthias Dr. Gossel
Karl-Heinz Dr. Nietsch
Gerhard Prof. Dr. Sattler
Gerhard Prof. Vogel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz Pharmaceuticals GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34529797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE10349979(B4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Priority to DE10349979A priority Critical patent/DE10349979B4/de
Priority to DE502004008793T priority patent/DE502004008793D1/de
Priority to PCT/EP2004/011320 priority patent/WO2005041919A2/de
Priority to HK07101847.6A priority patent/HK1096857B/xx
Priority to AU2004285264A priority patent/AU2004285264A1/en
Priority to KR1020067007762A priority patent/KR20060117914A/ko
Priority to MXPA06004081A priority patent/MXPA06004081A/es
Priority to BRPI0415756-7A priority patent/BRPI0415756A/pt
Priority to CA002543187A priority patent/CA2543187A1/en
Priority to EP04765912A priority patent/EP1684722B1/de
Priority to ES04765912T priority patent/ES2319997T3/es
Priority to AT04765912T priority patent/ATE418965T1/de
Priority to JP2006535989A priority patent/JP2007509085A/ja
Priority to CNB2004800314111A priority patent/CN100482211C/zh
Priority to US10/970,815 priority patent/US20050089555A1/en
Publication of DE10349979A1 publication Critical patent/DE10349979A1/de
Priority to IL174525A priority patent/IL174525A0/en
Publication of DE10349979B4 publication Critical patent/DE10349979B4/de
Application granted granted Critical
Priority to US12/459,952 priority patent/US20090275545A1/en
Priority to US13/357,423 priority patent/US20120329765A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE10349979A 2003-10-24 2003-10-24 Medikamentöse gezielte lokale Lipolyse Expired - Fee Related DE10349979B4 (de)

Priority Applications (18)

Application Number Priority Date Filing Date Title
DE10349979A DE10349979B4 (de) 2003-10-24 2003-10-24 Medikamentöse gezielte lokale Lipolyse
ES04765912T ES2319997T3 (es) 2003-10-24 2004-10-09 Lipolisis local selectiva medicamentosa.
JP2006535989A JP2007509085A (ja) 2003-10-24 2004-10-09 薬物標的化された局所的脂肪分解
HK07101847.6A HK1096857B (en) 2003-10-24 2004-10-09 Medicamentously targeted local lipolysis
AU2004285264A AU2004285264A1 (en) 2003-10-24 2004-10-09 Medicamentously targeted local lipolysis
KR1020067007762A KR20060117914A (ko) 2003-10-24 2004-10-09 약물을 사용한 표적화된 국소 부위의 지방 분해
MXPA06004081A MXPA06004081A (es) 2003-10-24 2004-10-09 Lipolisis local medicamentosa dirigida.
BRPI0415756-7A BRPI0415756A (pt) 2003-10-24 2004-10-09 lipólise medicamentosa local, dirigida
CA002543187A CA2543187A1 (en) 2003-10-24 2004-10-09 Medicamentously targeted local lipolysis
EP04765912A EP1684722B1 (de) 2003-10-24 2004-10-09 Medikamentöse gezielte lokale lipolyse
DE502004008793T DE502004008793D1 (cg-RX-API-DMAC7.html) 2003-10-24 2004-10-09
AT04765912T ATE418965T1 (de) 2003-10-24 2004-10-09 Medikamentöse gezielte lokale lipolyse
PCT/EP2004/011320 WO2005041919A2 (de) 2003-10-24 2004-10-09 Medikamentöse gezielte lokale lipolyse
CNB2004800314111A CN100482211C (zh) 2003-10-24 2004-10-09 药物靶向的局部脂解
US10/970,815 US20050089555A1 (en) 2003-10-24 2004-10-21 Medicinal targeted local lipolysis
IL174525A IL174525A0 (en) 2003-10-24 2006-03-23 Medicamentously targeted local lipolysis
US12/459,952 US20090275545A1 (en) 2003-10-24 2009-07-10 Medicinal targeted local lipolysis
US13/357,423 US20120329765A1 (en) 2003-10-24 2012-01-24 Medicinal targeted local lipolysis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10349979A DE10349979B4 (de) 2003-10-24 2003-10-24 Medikamentöse gezielte lokale Lipolyse

Publications (2)

Publication Number Publication Date
DE10349979A1 DE10349979A1 (de) 2005-06-16
DE10349979B4 true DE10349979B4 (de) 2006-05-18

Family

ID=34529797

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10349979A Expired - Fee Related DE10349979B4 (de) 2003-10-24 2003-10-24 Medikamentöse gezielte lokale Lipolyse
DE502004008793T Expired - Lifetime DE502004008793D1 (cg-RX-API-DMAC7.html) 2003-10-24 2004-10-09

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE502004008793T Expired - Lifetime DE502004008793D1 (cg-RX-API-DMAC7.html) 2003-10-24 2004-10-09

Country Status (13)

Country Link
EP (1) EP1684722B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007509085A (cg-RX-API-DMAC7.html)
KR (1) KR20060117914A (cg-RX-API-DMAC7.html)
CN (1) CN100482211C (cg-RX-API-DMAC7.html)
AT (1) ATE418965T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004285264A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0415756A (cg-RX-API-DMAC7.html)
CA (1) CA2543187A1 (cg-RX-API-DMAC7.html)
DE (2) DE10349979B4 (cg-RX-API-DMAC7.html)
ES (1) ES2319997T3 (cg-RX-API-DMAC7.html)
IL (1) IL174525A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06004081A (cg-RX-API-DMAC7.html)
WO (1) WO2005041919A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10361067A1 (de) * 2003-12-22 2005-07-14 Aventis Pharma Deutschland Gmbh Medikamentöse Lipolyse von Fettansammlungen
ES2372499T3 (es) * 2004-05-19 2012-01-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Uso de un detergente para la eliminación no quirúrgica de grasa.
DE102007015701A1 (de) 2007-03-19 2008-09-25 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue pharmazeutische Zusammensetzungen für die Lipolyse und Verfahren zu deren Herstellung
CN102481305B (zh) 2009-08-25 2015-08-19 美德阿利克斯株式会社 磷脂酰胆碱的经皮组合物及其制备方法
DE102010028365A1 (de) * 2010-04-29 2011-11-03 Lichtblick Gmbh Verwendung einer Phospholipid enthaltenden Zusammensetzung zur Entfernung von subkutanen Fettansammlungen
KR101353443B1 (ko) * 2012-02-07 2014-01-29 주식회사 아미팜 데옥시콜린산 나트륨이 없는 포스파티딜콜린 함유 주사제 조성물 및 이의 제조방법
BR112014029188B1 (pt) * 2012-05-31 2020-02-11 Terumo Kabushiki Kaisha Veículo sensível ao ph e método de preparação do mesmo, e droga sensível ao ph e composição medicamentosa sensível ao ph contendo o veículo, e método de cultura usando o mesmo
BR112016030341A8 (pt) * 2014-06-27 2021-07-20 Medytox Inc formulação para a remoção não cirúrgica de um depósito de gordura localizada em um indivíduo, método para a remoção não cirúrgica de depósitos de gordura localizada em um indivíduo que tem acúmulo de gordura localizada, e kit
US9687455B2 (en) 2014-08-14 2017-06-27 John Daniel Dobak Sodium tetradecyl sulfate formulations for treatment of adipose tissue
US12616651B2 (en) 2014-11-21 2026-05-05 Lipodissolve Therapeutics Inc. Topical lipolysis composition and methods
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
EP3479827B1 (en) 2017-04-21 2023-05-10 AMI Pharm Co., Ltd. Injectable composition for localized fat reduction without pain, edema, and side effects, and method for preparing same
KR101865562B1 (ko) * 2017-11-03 2018-06-08 주식회사 펜믹스 포스포콜린 유도체를 포함하는 지방분해 조성물
WO2019150594A1 (ja) 2018-01-31 2019-08-08 株式会社ユニッシュ ホスファチジルコリン経皮吸収製剤
KR20190095833A (ko) * 2018-02-07 2019-08-16 이기택 고통 및 부작용이 없는 국소지방 감소용 포스파티딜콜린 비포함 주사제 조성물
WO2019203543A1 (ko) * 2018-04-18 2019-10-24 (주)인벤티지랩 데옥시콜린산을 포함하는 피하 주사용 조성물 및 이의 제조 방법
KR102939043B1 (ko) 2020-06-01 2026-03-16 코스메드 파마소티컬 씨오 쩜 엘티디 미용용 마이크로니들 어레이
CN116889548B (zh) * 2022-03-31 2026-07-21 四川汇宇制药股份有限公司 一种脂质体递药系统及其制备方法和用途
KR20260079596A (ko) 2023-09-27 2026-06-02 쓰추안 휘위 파머슈티컬 컴퍼니., 리미티드. 리포좀 약물 전달 시스템 및 이의 제조 방법, 리포좀 제제, 용도, 이를 포함한 체지방 감소 약물 또는 의료 미용 제품

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2556592A1 (de) * 1975-12-16 1977-06-30 Nattermann A & Cie Arzneimittelzubereitungen auf basis oeliger loesungen von phospholipiden
EP0470437A1 (de) * 1990-08-06 1992-02-12 A. Nattermann & Cie. GmbH Wässriges Liposomensystem
EP0615746A1 (de) * 1993-03-15 1994-09-21 Rhone-Poulenc Rorer Gmbh Wässriges Liposomensystem sowie Verfahren zur Herstellung eines derartigen Liposomensystems

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556637A (en) * 1990-08-06 1996-09-17 A. Nattermann & Cie. Gmbh Water containing liposome system
ITMI20011182A1 (it) * 2001-06-05 2002-12-05 Indena Spa Composizioni farmaceutiche e/o cosmetiche per il trattamento di adiposita' localizzate e della cellulite

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2556592A1 (de) * 1975-12-16 1977-06-30 Nattermann A & Cie Arzneimittelzubereitungen auf basis oeliger loesungen von phospholipiden
EP0470437A1 (de) * 1990-08-06 1992-02-12 A. Nattermann & Cie. GmbH Wässriges Liposomensystem
EP0615746A1 (de) * 1993-03-15 1994-09-21 Rhone-Poulenc Rorer Gmbh Wässriges Liposomensystem sowie Verfahren zur Herstellung eines derartigen Liposomensystems

Also Published As

Publication number Publication date
CN100482211C (zh) 2009-04-29
KR20060117914A (ko) 2006-11-17
HK1096857A1 (zh) 2007-06-15
CN1870977A (zh) 2006-11-29
ATE418965T1 (de) 2009-01-15
WO2005041919A3 (de) 2005-06-23
DE502004008793D1 (cg-RX-API-DMAC7.html) 2009-02-12
EP1684722B1 (de) 2008-12-31
JP2007509085A (ja) 2007-04-12
EP1684722A2 (de) 2006-08-02
BRPI0415756A (pt) 2006-12-19
WO2005041919A2 (de) 2005-05-12
ES2319997T3 (es) 2009-05-18
CA2543187A1 (en) 2005-05-12
IL174525A0 (en) 2006-08-01
MXPA06004081A (es) 2006-06-27
DE10349979A1 (de) 2005-06-16
AU2004285264A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
EP1684722B1 (de) Medikamentöse gezielte lokale lipolyse
US20120329765A1 (en) Medicinal targeted local lipolysis
DE10361067A1 (de) Medikamentöse Lipolyse von Fettansammlungen
DE2907778C2 (cg-RX-API-DMAC7.html)
EP2563370B1 (de) Verwendung einer phospholipid und glycyrrhizinsäure enthaltenden zusammensetzung zur entfernung von subkutanen fettansammlungen durch subkutane lipolyse
US20100004216A1 (en) Medicinal lipolysis of accumulation of fat
DE1792410B2 (de) Arzneimittelzubereitung zur intravenösen Injektion
AT505086A1 (de) Pharmazeutisches mittel gegen juckreiz und juckreizbedingten schmerz
DE19810655A1 (de) Arzneimittel mit einem Gehalt an Ciclosporin
DE10221194B4 (de) Hyaluronidasehaltiges Hautpflegemittel
DE68903736T2 (de) Stabilisierte 2-phenyl-1,2-benzisoselenazol-3(2h)-on enthaltende, parenteral anzuwendende loesung und verfahren zu deren herstellung.
WO2008113421A1 (de) Neue pharmazeutische zusammensetzungen für die lipolyse und verfahren zu deren herstellung
DE602004001393T2 (de) Stabile pharmazeutische zusammensetzung mit safingol und verfahren zu dessen verwendung
EP2244693B1 (de) Mittel zur intraartikulären injektion
EP1913934A1 (de) Emulgatorfreies opthalmisches Präparat enthaltend Plflanzenöl
DE4121389A1 (de) Pharmazeutisches produkt zur behandlung von viruserkrankungen
DE202007004776U1 (de) Neue pharmazeutische Zusammensetzungen für die Lipolyse
DE2319473A1 (de) Ricinhaltiges pharmazeutisches material mit antikrebswirkung
WO1993013765A1 (fr) Solutions contenant des lecithines avec du levemopamil
HK1096857B (en) Medicamentously targeted local lipolysis
DE2401447A1 (de) Pharmazeutische zusammensetzung zur behandlung von hautproliferationserkrankungen

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8127 New person/name/address of the applicant

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, 65929 FRANKFURT,

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERZ PHARMACEUTICALS GMBH, 60318 FRANKFURT, DE

R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee

Effective date: 20130501